Moreover, adjuvant or neoadjuvant treatment of ErbB2-positive breast cancer with lapatinib and ErbB2-specific trastuzumab does not significantly improve disease-free survival, compared to trastuzumab alone [11, 12]. The gene discussed is ERBB2; the disease is breast carcinoma.